News & Events

November 08, 2021

Special Needs Families Average $18K in Lost Income Annually

According to a new article in Pediatrics, a significant number of caregivers of children with special needs reduce their work hours or stop working altogether in order to manage their child’s needs.

November 01, 2021

Community Shares | November 2nd, 2021

Individuals with ASD are 3 times more likely to self-harm than those without the disorder, according to a new systematic review and meta-analysis of 31 studies. The excess odds of self-harm were found in both children and adults across geographic regions and regardless of study designs, methods and settings.  A new study has examined the […]

November 01, 2021

Roadway Pollution More Toxic Than Freeway Pollution

A large, representative retrospective birth cohort study has discovered that in utero exposure to near-roadway air pollution (NRAP) from non-freeways was associated with an increased risk of autism spectrum disorder (ASD).

treating pre-symptomatic ASD visual
November 01, 2021

Target: Treating Pre-symptomatic ASD in the First and Second Years of Life

The current average age for autism diagnosis in the United States is four years and four months, which is an improvement from twenty years ago when the average age of diagnosis was closer to 5 years. 

New Jersey road sign
November 01, 2021

New Estimate Shows Communities in New Jersey Have an Autism Prevalence at 5 Percent or Higher

SafeMinds had the pleasure of conversing with Walter M. Zahorodny, Ph.D., co-author of the new report, “Prevalence of autism spectrum disorder in a large, diverse metropolitan area: Variation by sociodemographic factors.” He is an Associate Professor of Pediatrics at Rutgers New Jersey Medical School.

October 25, 2021

Community Shares | October 26th, 2021

The biotech company, Axial Therapeutics, has just added $37.25 million towards their effort to treat autism through the gut. In total, the company has raised over $90 million for its gut-brain axis research. These new funds will be used to conduct a Phase II trial of the company’s lead program, a gut-restricted molecular therapy for […]

Show Buttons
Hide Buttons